有任何意見歡迎留言或是私訊我的ig @hongyi_111111 使用到的論文： Knudsen LB and Lau J (2019) The Discovery and Development of Liraglutide and Semaglutide. Front. Endocrinol. 10:155. doi: 10.3389/fendo.2019.00155 Discovery of the Once-Weekly Glucagon-Like Peptide‑1 (GLP-1) Analogue Semaglutide Jesper Lau,* Paw Bloch, Lauge Schäffer, Ingrid Pettersson, Jane Spetzler, Jacob Kofoed, Kjeld Madsen,Lotte Bjerre Knudsen, James McGuire, Dorte Bjerre Steensgaard, Holger Martin Strauss, Dorte X. Gram,Sanne Møller Knudsen, Flemming Seier Nielsen, Peter Thygesen, Steffen Reedtz-Runge, and Thomas Kruse Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and designDonna H. Ryan, MD,a Ildiko Lingvay, MD, MPH, MSCS, b Helen M. Colhoun, MD,c John Deanfield, MD, d Scott S. Emerson, MD, PhD,e Steven E. Kahn, MB, ChB, f Robert F. Kushner, MD, g Steve Marso, MD, h Jorge Plutzky, MD, i Kirstine Brown-Frandsen, MD, j Marianne O. L. Gronning, DVM, DMSc, PhD, j G. Kees Hovingh, MD, PhD, j,k Anders Gaarsdal Holst, MD, PhD, j Henrik Ravn, MSc, PhD, j and A. Michael Lincoff, MD l Semaglutide: First Global Approval Sohita Dhillon1Drugs (2018) 78:275–284 https://doi.org/10.1007/s40265-018-0871-0 合作信箱：al2988082@gmail.com 生命科學不是做殯葬業的 -- Hosting provided by SoundOn